Treatment of HCV liver disease by recombinant interferon  | Zendy

François Bailly | Zendy; Nilu Si | Zendy; Akverova Si | Zendy; C. Trépo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of HCV liver disease by recombinant interferon

Author(s) -

François Bailly,

Nilu Si,

Akverova Si,

C. Trépo

Publication year - 1996

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/11.supp4.56

Subject(s) - medicine , ribavirin , interferon , interferon alfa , gastroenterology , chronic hepatitis , alpha interferon , viral disease , hepatitis c , recombinant dna , hepatitis c virus , liver disease , immunology , nucleoside , virus , biochemistry , chemistry , gene , stereochemistry

Interferon alpha has confirmed its efficacy for the therapy of chronic hepatitis C. Half of the patients treated will normalize their plasma ALT at the end of a 6-month course of 3 MU thrice a week. This biochemical response is associated with a reduction of HCV RNA (viraemia) from serum and with significant improvement of liver histology. Despite those beneficial effects, 50% of treatment responders generally relapse after treatment arrest. Increasing doses to 6 MU and/or the duration of interferon therapy increases the proportion of long-term sustained responders. Combining therapy with ribavirin, a nucleoside analogue, also appears to have a similar effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research